Background: Diabetes, a metabolic disease, occurs due to a decreased or no effect of
insulin on the blood glucose level. The current oral medications stimulate insulin release …

Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones,
glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus …

Diabetes Mellitus (Type 2) is a major health issue all over the world. It is rapidly growing
metabolic disorder characterized by hyperglycaemia with disturbances in carbohydrate, fat …

New therapeutic agents are needed to combat the ever-increasing prevalence of diabetes.
The two incretins glucagon-like peptide-1 (7-36)(GLP-1 (7-36)) amide and glucose …

ABSTRACT Glucagon-like peptide-1 (GLP-1), one kind of incretins, contributes to control
blood glucose level with several routines. It can be degraded rapidly by the enzyme …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP-1) are
the 2 major incretin hormones released after meals to enhance glucose-stimulated insulin …

Introduction: The serine exopeptidase DPP IV is a dual protein able to work as an enzyme
and an interacting protein. The incretin molecules glucagon-like peptide 1 (GLP-1) and …

Dipeptidyl peptidase IV (DPP4) is a promising target for the treatment of chronic metabolic
type 2 diabetes mellitus (T2D). DPP4 is a highly specific serine protease involved in the …

Diabetes mellitus is a chronic disease characteristic of poor glucose homeostasis that
requires constant monitoring and adjustment of blood glucose levels by exogenous …

The enzyme, dipeptidyl peptidase IV (DPP IV), is a novel target for the treatment of type 2
diabetes. Dipeptidyl peptidase IV inhibition improves the impaired insulin secretion and …